Tenderwize
Wróć do wyszukiwania

Framework agreement for CAR-T cell therapy active ingredients

Azienda ULSS n. 8 Berica·Vicenza, Italy·EUR 19.4M·Expired · Jul 06, 2026·Open·Supplies·Framework
High valueStructured notice only
Oryginalny tytuł ogłoszenia

Italy – Antineoplastic and immunomodulating agents – GARA EUROPEA A PROCEDURA APERTA PER LA FORNITURA, IN ACCORDO QUADRO MULTIFORNITORE, DI PRINCIPI ATTIVI PER TERAPIE CON CELLULE CAR-T DESTINATE A PAZIENTI IN CARICO ALL’AZIENDA ULSS N. 8 BERICA

30/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkExpired
Skąd ta ocena?

Szansa

30 / 100

Złożoność

60 / 100

Czynniki ryzyka

The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...

EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • EUR 19.4M estimated value
  • Framework procurement
  • Supplies contract
  • 3 lots
  • Duration 12 MONTH
  • Supply of active principles (pharmaceutical substances) for CAR-T cell therapies.
  • The products are intended for specific lymphoma indications: DLBCL (2nd and 3rd line), PMBCL (3rd line), and follicular lymphoma (4th line).
Pokaż pełne podsumowanie

This is an open procedure tender for a multi-supplier framework agreement for the supply of active principles for CAR-T cell therapies, intended for patients under the care of Azienda ULSS n. 8 Berica (Italy). The tender is divided into three lots covering specific lymphoma therapies. The procedure is currently suspended due to a complaint (reclamo) as per the XML notice. The estimated total value across lots is €19,401,945. Award is based solely on price. Submission deadline is 2026-07-06 (10:00 or 12:00 – inconsistency noted). Important documents (e.g., ESPD) are required. EU funding status is inconsistent between structured data (EU-funded) and XML notice (no EU funds). The notice is in Italian only.

Ryzyka

The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...

EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Certifications

  • All communications and submissions must be electronic via Sintel or certified email (PEC) for Italian operators, or qualified electronic registered delivery service for...

Administrative

  • Registration on the Sintel e-procurement platform (ARIA SPA) is mandatory.
  • Tender must be accompanied by the European Single Procurement Document (ESPD) or equivalent.

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

Award criterion: price only (lowest price).

Lot 2

Award criterion: price only (lowest price).

Lot 3

Award criterion: price only (lowest price).

Zamawiający

Lokalizacja

Vicenza, ITA

Profil zamawiającego

Otwórz profil

Identyfikator

02441500242

Działalność

Health

Części (3)

LOT-0001

LOTTO 1 - Therapy for adult patients with DLBCL Lymphoma - 2nd Line and Therapy for adult patients with PMBCL Lymphoma - 3rd Line

Supply of active principles for CAR-T therapy for adult patients with DLBCL (2nd line) and PMBCL (3rd line). Framework agreement with a maximum value of €15,936,345, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Szacowana wartość

Czas trwania

12 MONTH

Kategoria

Antineoplastic and immunomodulating agents

Kryteria udzielenia

Price

Termin

Expired Jul 06, 2026

LOT-0002

LOTTO 2 - Therapy for adult patients with DLBCL Lymphoma - 3rd Line

Supply of active principles for CAR-T therapy for adult patients with DLBCL (3rd line). Framework agreement with a maximum value of €1,732,800, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Szacowana wartość

Czas trwania

12 MONTH

Kategoria

Antineoplastic and immunomodulating agents

Kryteria udzielenia

Price

Termin

Expired Jul 06, 2026

LOT-0003

LOTTO 3 - Therapy for adult patients with Follicular Lymphoma (FL) - 4th Line

Supply of active principles for CAR-T therapy for adult patients with follicular lymphoma (4th line). Framework agreement with a maximum value of €1,732,800, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Szacowana wartość

Czas trwania

12 MONTH

Kategoria

Antineoplastic and immunomodulating agents

Kryteria udzielenia

Price

Termin

Expired Jul 06, 2026

Szczegóły zamówienia

Data publikacji
02 Jul 2026
Języki
Italian

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
456933-2026

Dokumenty (2)

Podobne przetargi